SAT0374 Lesinurad (LESU) adjunctive therapy with allopurinol (ALLO) in patients not responding to allo monotherapy: pooled post hoc safety and efficacy analysis in a patient subgroup using concomitant diuretics at baseline (BL)

Background LESU is approved as adjunctive therapy in combination with xanthine oxidase inhibitors (XOI) for gout PT not responding to XOI alone 1 . Gout PT often have hypertension (HT) for which diuretics especially thiazide and thiazide-like diuretics (TTLD) are prescribed. TTLD contributes to hyperuricemia 2 by acting on OAT4 transporter, which is inhibited by LESU. Objectives To assess the efficacy and safety of LESU+ALLO in the subgroup of PT using concomitant diuretics at BL in CLEAR 1 and CLEAR 2, two randomised, double-blind, placebo-controlled Phase 3 studies that evaluated LESU200/400 mg daily in combination with ALLO vs ALLO +placebo. 3&4 . Methods Data from both trials of 1,213 PT, was pooled and PT group using diuretics at baseline was compared to non-users with respect to sUA target and TEAE. Results Totally 221 PT received diuretics,>90% due to HT and ~80% being TTLD. In both groups, LESU +ALLO doubled the number of PT reaching sUA target of Conclusions LESU +ALLO doubled the number of PT reaching sUA target of References [1] Zurampic®(lesinurad) SmPC. Grunenthal GmbH, February 2016. [2] Bruderer S, et al. Arthritis Rheumatol2014Jan;66(1):185–96. [3] Saag KG, et al. Arthritis Rheumatol2017;69:203–12. [4] Bardin T, et al. Ann Rheum Dis2017;76:811–20. Disclosure of Interest T. Bardin Grant/research support from: Astrazeneca, Ipsen, Menarini, Consultant for: Grunenthal, Speakers bureau: Astrazeneca, Ipsen, Menarini, Grunenthal, Novartis, R. Karra Employee of: Grunenthal, A. So Consultant for: Grunnenthal, Sobi, A.-K. Tausche Consultant for: Berlin-Chemie, Menarini, Ipsen, Sobi, Novartis, Ardea Biosciences/AstraZeneca, I. Wild Employee of: Grunenthal, H. Hagedorn Employee of: Grunenthal, P. Kandaswamy Employee of: Grunenthal, F. Perez-Ruiz Consultant for: Grunenthal, Menarini, Spanish Society of Rheumatology, Cruces Hospital Rheumatology Association.